Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages

  Van Rooij, Nienke ^a   Van Buuren, Marit M ^a   Philips, Daisy ^a   Velds, Arno ^a   Toebes, Mireille ^a   Heemskerk, Bianca ^a   Van Dijk, Laura J A ^a   Behjati, Sam ^b   Hilkmann, Henk ^a   El Atmioui, Dris ^a   Nieuwland, Marja ^a   Stratton, Michael R ^b   Kerkhoven, Ron M ^a   Keşmir, Can ^c   Haanen, John B ^a   Kvistborg, Pia ^a   Schumacher, Ton N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CYTOCHROME; CYTOCHROME 7; DACARBAZINE; FLUORODEOXYGLUCOSE F 18; HLA A ANTIGEN; HLA A3 ANTIGEN; HLA A32 ANTIGEN; HLA B35 ANTIGEN; HLA B40 ANTIGEN; IPILIMUMAB; PROTEIN S100B; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA; MONOCLONAL ANTIBODY;

ADULT; AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; AXILLARY LYMPH NODE; BINDING AFFINITY; BRAIN CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; CD8+ T LYMPHOCYTE; CODON; COMPASSIONATE USE; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DRUG TOLERABILITY; GENE DELETION; GENE EXPRESSION; GENE PRODUCT; GENOME ANALYSIS; HUMAN; IMMUNOREACTIVITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NONSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; STEREOTACTIC RADIOSURGERY; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR EXOME ANALYSIS; TUMOR IMMUNITY; EXOME; GENETICS; IMMUNOLOGY; SKIN TUMOR; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; EXOME; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84872841412     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.7521     Document Type: Article

References (22)

1. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
2. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
3. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
4. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J 32:194-203, 2013
5. Kvistborg P, Shu CJ, Heemskerk B, et al: TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1:409-418, 2012
6. Yuan J, Adamow M, Ginsberg BA, et al: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108:16723-16728, 2011
7. Segal NH, Parsons DW, Peggs KS, et al: Epitope landscape in breast and colorectal cancer. Cancer Res 68:889-892, 2008 (Pubitemid 351206767)
8. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-263, 2012
9. Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-1014, 2012
10. Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-446, 2011
11. Castle JC, Kreiter S, Diekmann J, et al: Exploiting the mutanome for tumor vaccination. Cancer Res 72:1081-1091, 2012
12. Matsushita H, Vesely MD, Koboldt DC, et al: Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400-404, 2012
13. Lundegaard C, Lamberth K, Harndahl M, et al: NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36:W509-W512, 2008
14. Nielsen M, Lundegaard C, Worning P, et al: Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 20:1388-1397, 2004 (Pubitemid 38937025)
15. Nielsen M, Lundegaard C, Lund O, et al: The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57:33-41, 2005 (Pubitemid 40591245)
16. Rodenko B, Toebes M, Hadrup SR, et al: Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 1:1120-1132, 2006
17. Toebes M, Coccoris M, Bins A, et al: Design and use of conditional MHC class I ligands. Nat Med 12:246-251, 2006 (Pubitemid 43214754)
18. Hadrup SR, Bakker AH, Shu CJ, et al: Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 6:520-526, 2009
19. Andersen RS, Kvistborg P, Frøsig TM, et al: Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 7:891-902, 2012
20. Cimprich KA, Cortez D: ATR: An essential regulator of genome integrity. Nat Rev Mol Cell Biol 9:616-627, 2008 (Pubitemid 352032926)
21. Kroemer G, Zitvogel L: Can the exome and the immunome converge on the design of efficient cancer vaccines? Oncoimmunology 1:579-580, 2012
22. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-752, 2013